| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/JAMA.2013.279201 |
| P698 | PubMed publication ID | 24104372 |
| P50 | author | Andreas Hochhaus | Q37829812 |
| Marco Niedergethmann | Q40929179 | ||
| Peter Neuhaus | Q71350587 | ||
| P2093 | author name string | Hanno Riess | |
| Jörg Thomas Hartmann | |||
| Axel Hinke | |||
| Karsten Ridwelski | |||
| Klaus Gellert | |||
| Helmut Oettle | |||
| Jörg Fahlke | |||
| Carl Zülke | |||
| Marianne Sinn | |||
| Michael B Arning | |||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| patient | Q181600 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 1473-1481 | |
| P577 | publication date | 2013-10-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial | |
| P478 | volume | 310 |
| Q92235876 | 64Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer |
| Q64238249 | A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer |
| Q30238706 | A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review |
| Q64117825 | A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance) |
| Q54353515 | A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. |
| Q36866706 | A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy |
| Q41813308 | A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels |
| Q47731653 | A look at the progress of treating pancreatic cancer over the past 20 years |
| Q41598569 | A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic adenocarcinoma |
| Q90609154 | A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection |
| Q35761097 | A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma |
| Q36130588 | A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol |
| Q42690847 | A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice |
| Q26748880 | A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma |
| Q89450257 | Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling |
| Q51563833 | Adjuvant Hepatic Arterial Infusion Chemotherapy After Resection for Pancreatic Cancer Using Coaxial Catheter-Port System Compared with Conventional System. |
| Q30277400 | Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis |
| Q37191059 | Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma |
| Q38736437 | Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials. |
| Q39707839 | Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). |
| Q93379624 | Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005 |
| Q35851281 | Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. |
| Q55401908 | Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy. |
| Q26775916 | Adjuvant therapy for pancreas cancer in an era of value based cancer care |
| Q64069471 | Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database |
| Q24186323 | Adjuvant therapy for resected pancreatic cancer |
| Q94327146 | Adjuvant therapy for resected pancreatic cancer |
| Q33593250 | Adjuvant therapy in biliary tract and gall bladder carcinomas: a review |
| Q39389872 | Adjuvant treatment for pancreatic ductal carcinoma |
| Q49178298 | Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study |
| Q36400058 | Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer |
| Q43227215 | Advanced pancreatic cancer - how to choose an adequate treatment option |
| Q28085711 | Advances in chemotherapy for pancreatic cancer |
| Q26798674 | Albumin-bound paclitaxel in solid tumors: clinical development and future directions |
| Q38703429 | Algenpantucel-L immunotherapy in pancreatic adenocarcinoma |
| Q50081432 | An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). |
| Q40987835 | An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses |
| Q90618621 | An update on treatment options for pancreatic adenocarcinoma |
| Q92103398 | Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution |
| Q38804328 | Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic Cancer |
| Q37706025 | Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea |
| Q39262474 | Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma |
| Q33874242 | Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy |
| Q92614597 | Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer |
| Q50137552 | BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. |
| Q47317142 | Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts. |
| Q26752755 | Biomarkers and Targeted Therapy in Pancreatic Cancer |
| Q64069779 | Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer |
| Q99614738 | Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities |
| Q36464837 | CA724 is a novel factor for predicting the unresectability in pancreatic adenocarcinoma |
| Q89184431 | CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis |
| Q91976213 | Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer |
| Q34431614 | Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma |
| Q26746031 | Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question? |
| Q33876637 | Chemotherapy and tumor microenvironment of pancreatic cancer. |
| Q55000756 | Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. |
| Q92026475 | Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma |
| Q34896914 | Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma |
| Q38726457 | Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer |
| Q50853969 | Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting. |
| Q91695476 | Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer |
| Q35970766 | Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol |
| Q42373339 | Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. |
| Q45063614 | Clinical study of genomic drivers in pancreatic ductal adenocarcinoma |
| Q58610296 | Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine |
| Q40631094 | Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. |
| Q47568968 | Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy |
| Q38994795 | Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial |
| Q61811947 | Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review |
| Q90344928 | Completion of adjuvant therapy in patients with resected pancreatic cancer |
| Q35737695 | Conditional survival of pancreatic ductal adenocarcinoma in surgical and nonsurgical patients: a retrospective analysis report from a single institution in China |
| Q33665450 | Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. |
| Q97535513 | Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position |
| Q47716584 | Contemporary Management of Localized Resectable Pancreatic Cancer |
| Q57485825 | Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial |
| Q90194029 | Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions |
| Q52628886 | Current Concepts in the Treatment of Resectable Pancreatic Cancer. |
| Q38673621 | Current and future therapies for advanced pancreatic cancer |
| Q36335693 | Cyclin G2: A novel independent prognostic marker in pancreatic cancer |
| Q38789903 | Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. |
| Q47547107 | Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma |
| Q35922334 | Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis |
| Q64064260 | Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients |
| Q64063175 | Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients |
| Q40729761 | Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. |
| Q53098497 | Determinants of Outcomes Following Resection for Pancreatic Cancer-a Population-Based Study. |
| Q92038402 | Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer |
| Q48622261 | Different survival benefits of Chinese medicine for pancreatic cancer: How to choose? |
| Q61445866 | Dissected peripancreatic tissue margin is a critical prognostic factor and is associated with a gene mutation in pancreatic ductal adenocarcinoma |
| Q38662233 | Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity |
| Q44743232 | Distal pancreatectomy for pancreatic carcinoma in the era of multimodal treatment. |
| Q53113663 | Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma? |
| Q40331119 | Does long-term survival exist in pancreatic adenocarcinoma? |
| Q64997389 | Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study. |
| Q37364111 | Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. |
| Q33832655 | Ductal pancreatic adenocarcinoma |
| Q48107797 | EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer. |
| Q37412058 | Early Recurrence and Omission of Adjuvant Therapy after Pancreaticoduodenectomy Argue against a Surgery-First Approach. |
| Q61805778 | Early reoperation following pancreaticoduodenectomy: impact on morbidity, mortality, and long-term survival |
| Q36310710 | Early versus delayed initiation of adjuvant treatment for pancreatic cancer |
| Q38972462 | Effect of postoperative major complications on prognosis after pancreatectomy for pancreatic cancer: a retrospective review |
| Q92665776 | Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study |
| Q36171310 | Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). |
| Q33417372 | Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study |
| Q39025906 | Endoscopic ultrasound in pancreatic cancer: innovative applications beyond the basics |
| Q90062349 | Environmental Risk Factors of Pancreatic Cancer |
| Q64236675 | Epithelial-mesenchymal transition via transforming growth factor beta in pancreatic cancer is potentiated by the inflammatory glycoprotein leucine-rich alpha-2 glycoprotein |
| Q36161168 | Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis |
| Q38624806 | Evolving treatment landscape for early and advanced pancreatic cancer |
| Q52668506 | Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. |
| Q44993391 | Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. |
| Q41888817 | Extended versus peripancreatic lymph node dissection for the treatment of left-sided pancreatic cancer |
| Q48301473 | Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. |
| Q39419609 | Factors influencing receipt of adjuvant chemotherapy after surgery for pancreatic cancer: a two-center retrospective cohort study |
| Q41521606 | Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer |
| Q53643951 | Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. |
| Q37174939 | Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer |
| Q39039179 | Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective |
| Q37584952 | Focused update on Gastrointestinal (GI) Oncology from ASCO 2016. |
| Q37631655 | From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers |
| Q34221829 | Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma |
| Q41363526 | Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). |
| Q92448234 | Gas Plasma-Conditioned Ringer's Lactate Enhances the Cytotoxic Activity of Cisplatin and Gemcitabine in Pancreatic Cancer In Vitro and In Ovo |
| Q45992759 | Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence. |
| Q92713234 | Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review |
| Q38646222 | Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing |
| Q39706900 | Global Trends in Pancreatic Cancer Mortality From 1980 Through 2013 and Predictions for 2017. |
| Q37564518 | Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study. |
| Q90404450 | High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: A cohort study |
| Q38851735 | High-grade pancreatic intraepithelial lesions: prevalence and implications in pancreatic neoplasia. |
| Q38287286 | Histological and Molecular Subclassification of Pancreatic and Nonpancreatic Periampullary Cancers: Implications for (Neo) Adjuvant Systemic Treatment |
| Q91858994 | Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers |
| Q47816414 | Identification of Educational Gaps Among Oncologists Who Manage Patients with Pancreatic Cancer |
| Q88570154 | Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation |
| Q26828959 | Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles |
| Q60044566 | Immunotherapy and pancreatic cancer: unique challenges and potential opportunities |
| Q40462627 | Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer. |
| Q41545288 | Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study |
| Q99585289 | Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology program |
| Q41863407 | Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy. |
| Q38263106 | Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods |
| Q42419195 | Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death |
| Q88865537 | Improving post-surgical management of resected pancreatic cancer |
| Q52663568 | Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. |
| Q36195812 | Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment |
| Q37525354 | Investigating the prognostic value of KOC (K homology domain containing protein overexpressed in cancer) overexpression after curative intent resection of pancreatic ductal adenocarcinoma |
| Q38604399 | Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? |
| Q47319862 | Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study |
| Q39419994 | Is Pancreatic Head Cancer with Portal Venous Involvement Really Borderline Resectable? Appraisal of an Upfront Surgery Series |
| Q90723494 | Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? |
| Q30250097 | K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis |
| Q35875903 | LDP vs ODP for pancreatic adenocarcinoma: a case matched study from a single-institution |
| Q90052765 | Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review |
| Q38572073 | Laparoscopic Pancreaticoduodenectomy: Is It an Effective Procedure for Pancreatic Ductal Adenocarcinoma? |
| Q53186352 | Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Adenocarcinoma. |
| Q26799434 | Laparoscopic distal pancreatectomy for adenocarcinoma: safe and reasonable? |
| Q90643901 | Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma |
| Q35761091 | Long-term survival after resection for non-pancreatic periampullary cancer followed by adjuvant intra-arterial chemotherapy and concomitant radiotherapy |
| Q51107700 | Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. |
| Q45304734 | Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. |
| Q37431673 | MGDG extracted from spinach enhances the cytotoxicity of radiation in pancreatic cancer cells |
| Q34229432 | Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study |
| Q50071311 | Management Controversies and Treatment Strategies for Borderline Resectable Pancreatic Cancer. |
| Q38823634 | Management of Type 9 Hepatic Arterial Anatomy at the time of Pancreaticoduodenectomy: Considerations for Preservation and Reconstruction of a Completely Replaced Common Hepatic Artery. |
| Q26774639 | Management of pancreatic cancer in the elderly |
| Q52597920 | Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis. |
| Q49504793 | Medical oncology and pancreatic cancer: what the radiologist needs to know |
| Q36640493 | Meta-analyses of treatment standards for pancreatic cancer |
| Q39314886 | Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. |
| Q57795874 | Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone |
| Q47339502 | Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine |
| Q41111798 | Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer |
| Q35438928 | MiR-371-5p facilitates pancreatic cancer cell proliferation and decreases patient survival |
| Q26799779 | MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? |
| Q37564481 | MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis |
| Q37735617 | MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy |
| Q37696126 | MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells |
| Q50119514 | Microscopic Venous Invasion in Pancreatic Cancer |
| Q35834208 | Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma |
| Q52927231 | Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. |
| Q47813912 | Molecular landscape of pancreatic cancer: challenges and clinical implications |
| Q26824528 | Molecular landscape of pancreatic cancer: implications for current clinical trials |
| Q36666663 | Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy |
| Q39061625 | Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas |
| Q89944216 | Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis |
| Q39604971 | National disparities in minimally invasive surgery for pancreatic tumors |
| Q37625229 | Negative oncologic impact of poor postoperative pain control in left-sided pancreatic cancer. |
| Q90594477 | Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis |
| Q90413913 | Neoadjuvant Treatment in Pancreatic Cancer |
| Q89823499 | Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer |
| Q58611183 | Neoadjuvant and adjuvant chemotherapy in pancreatic cancer |
| Q34891512 | Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial |
| Q95320481 | Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis |
| Q26766686 | Neoadjuvant radiotherapeutic strategies in pancreatic cancer |
| Q27004292 | Neoadjuvant therapy for pancreas cancer: past lessons and future therapies |
| Q37460276 | Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer |
| Q64092030 | Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis |
| Q91012408 | Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis |
| Q42374126 | Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. |
| Q30249814 | Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer |
| Q28082422 | New challenges in perioperative management of pancreatic cancer |
| Q41436389 | Non-thermal plasma-treated solution demonstrates antitumor activity against pancreatic cancer cells in vitro and in vivo |
| Q26799425 | Novel adjuvant therapies for pancreatic adenocarcinoma |
| Q47701382 | Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. |
| Q38357201 | Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. |
| Q93234403 | Novel prognostic markers within the CD44-stromal ligand network in pancreatic cancer |
| Q36413415 | OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo |
| Q39240683 | Oncolytic viral therapy for pancreatic cancer. |
| Q91750166 | Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study |
| Q45735746 | Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis |
| Q58802147 | Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma |
| Q40342329 | Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. |
| Q64052211 | Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study |
| Q47110609 | Overexpression and biological function of MEF2D in human pancreatic cancer |
| Q34778217 | Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis |
| Q28079735 | Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language |
| Q36344551 | Pancreatic Cancer: Progress in Systemic Therapy |
| Q63865722 | Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT |
| Q39390859 | Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies |
| Q51009769 | Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Association Française de Chirurgie. |
| Q27008346 | Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy |
| Q57423198 | Pancreatic cancer |
| Q87198210 | Pancreatic cancer |
| Q35755386 | Pancreatic cancer and FOLFIRINOX: a new era and new questions |
| Q90263911 | Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer |
| Q26747524 | Pancreatic cancer from bench to bedside: molecular pathways and treatment options |
| Q59334865 | Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes |
| Q40261599 | Pancreatic cancer: Update on immunotherapies and algenpantucel-L. |
| Q38354856 | Pancreatic cancer: diagnosis and treatments |
| Q38396634 | Pancreatic cancer: from state-of-the-art treatments to promising novel therapies |
| Q52840059 | Pancreatic cancer: moving forward, step by step. |
| Q26799714 | Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies |
| Q30250026 | Pancreatic cancer: yesterday, today and tomorrow. |
| Q89476437 | Pancreatic ductal adenocarcinoma: a radiomics nomogram outperforms clinical model and TNM staging for survival estimation after curative resection |
| Q38724284 | Particle Radiation Therapy for Gastrointestinal Cancers |
| Q38566193 | Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort |
| Q91589102 | Pathological complete response (pCR) with or without the residual intraductal carcinoma component following preoperative treatment for pancreatic cancer: Revisiting the definition of "pCR" from the prognostic standpoint |
| Q64256637 | Pathomorphological features of metastatic lymph nodes as predictors of postoperative prognosis in pancreatic cancer |
| Q50493922 | Patients Treated with Preoperative Chemoradiation for Pancreatic Ductal Adenocarcinoma have Impaired Bone Density, a Predictor of Distant Metastasis. |
| Q89376945 | Pattern, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma: how do they matter? |
| Q53580027 | Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. |
| Q26801411 | Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma |
| Q47330535 | Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma |
| Q26753854 | Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival |
| Q26797248 | Perspectives in the treatment of pancreatic adenocarcinoma |
| Q28066320 | Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer |
| Q33431711 | Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer |
| Q39175584 | Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients |
| Q41620442 | Plasma membrane expression of ZNF185 is a prognostic factor in pancreatic ductal carcinoma |
| Q52726017 | Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. |
| Q88380410 | Poorly differentiated ductal adenocarcinoma of the pancreas with rapid progression in a young man |
| Q92258093 | Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer |
| Q50603465 | Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. |
| Q55274465 | Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. |
| Q46177219 | Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. |
| Q39985070 | Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer |
| Q90067362 | Precision medicine in pancreatic cancer: treating every patient as an exception |
| Q39040017 | Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study. |
| Q101216961 | Prediction of survival and recurrence in patients with pancreatic cancer by integrating multi-omics data |
| Q37367887 | Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level |
| Q60302342 | Preliminary application of 3D-printed coplanar template for iodine-125 seed implantation therapy in patients with advanced pancreatic cancer |
| Q52578010 | Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard? |
| Q64104061 | Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study |
| Q49072822 | Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma |
| Q90106949 | Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study |
| Q37576457 | Preoperative predictors for early recurrence of resectable pancreatic cancer |
| Q88443486 | Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer |
| Q38948847 | Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis. |
| Q34515112 | Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma |
| Q47141291 | Prognostic impact of carbohydrate antigen 19-9 level at diagnosis in resected stage I-III pancreatic adenocarcinoma: a U.S. population study |
| Q89810096 | Prognostic impact of lymph node status in patients after total pancreatectomy for pancreatic ductal adenocarcinoma: A strobe-compliant study |
| Q41758043 | Prognostic relevance of apparent diffusion coefficient obtained by diffusion-weighted MRI in pancreatic cancer |
| Q36103351 | Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma |
| Q42373321 | Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer |
| Q41566970 | Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer |
| Q35086475 | Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis |
| Q42700661 | Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature |
| Q99403350 | Promising xenograft animal model recapitulating the features of human pancreatic cancer |
| Q58706746 | Proposal of a modified American Joint Committee on Cancer staging scheme for resectable pancreatic ductal adenocarcinoma with a lymph node ratio-based N classification: A retrospective cohort study |
| Q92794998 | Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment |
| Q38777938 | Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact |
| Q90346450 | Proton beam radiotherapy for pancreas cancer |
| Q24186132 | Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma |
| Q58765908 | R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy |
| Q38765467 | RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4 |
| Q42425254 | Racial Disparities in the Outcomes of Patients With Stage IV Pancreatic Adenocarcinoma Are Mediated by Chemotherapy Utilization |
| Q89502157 | Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States |
| Q93041688 | Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines |
| Q50072347 | Recent advances in the management of pancreatic adenocarcinoma |
| Q90149903 | Recent advances in the treatment of pancreatic cancer |
| Q37117829 | Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis |
| Q64074237 | Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma |
| Q41721785 | Refining the American Joint Committee on Cancer Staging Scheme For Resectable Pancreatic Ductal Adenocarcinoma Using Recursive Partitioning Analysis |
| Q36326886 | Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management |
| Q53618459 | Research gaps in pancreatic cancer research and comparative effectiveness research methodologies. |
| Q90447790 | Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study) |
| Q57767420 | Resektion beim fortgeschrittenen Pankreaskarzinom nach multimodaler Vorbehandlung |
| Q94465308 | Response to Preoperative Therapy in Localized Pancreatic Cancer |
| Q60922820 | Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma |
| Q93238131 | Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer |
| Q89629982 | Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer-a distinct view on lymph node yield |
| Q34467156 | S-1 in the treatment of pancreatic cancer |
| Q44088489 | SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. |
| Q35528619 | Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma |
| Q92055156 | Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma |
| Q55162030 | Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. |
| Q55332247 | Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database. |
| Q38783194 | Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions |
| Q36161839 | Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report |
| Q26781546 | Surgery for oligometastasis of pancreatic cancer |
| Q89994907 | Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort |
| Q50526996 | Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma. |
| Q92354840 | Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis |
| Q37732028 | Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study. |
| Q57296505 | Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma |
| Q38200922 | Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal adenocarcinoma. |
| Q89735164 | TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial |
| Q91967736 | TIMP-2 secreted by monocyte-like cells is a potent suppressor of invadopodia formation in pancreatic cancer cells |
| Q38204280 | TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. |
| Q34260205 | Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells |
| Q37539690 | The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy |
| Q36188807 | The Impact of Socioeconomic Status, Surgical Resection and Type of Hospital on Survival in Patients with Pancreatic Cancer. A Population-Based Study in The Netherlands |
| Q64950912 | The Management of Older Adults with Pancreatic Adenocarcinoma. |
| Q48599351 | The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. |
| Q39808419 | The Results of Pancreatic Resections and Long-Term Survival for Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience. |
| Q92327996 | The Role of Systemic Inflammation in Cancer-Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention |
| Q92155365 | The Spectrum of Pulmonary Toxicity in Pancreatic Cancer Patients Receiving Gemcitabine Combination Chemotherapy |
| Q58785039 | The Utility of Preoperative Vascular Grading in Patients Undergoing Surgery First for Pancreatic Cancer: Does Radiologic Arterial or Venous Involvement Predict Pathologic Margin Status? |
| Q36747432 | The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection |
| Q87861013 | The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy |
| Q33919105 | The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis |
| Q88709397 | The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy |
| Q93019033 | The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma |
| Q91651431 | The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy |
| Q37605485 | The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity |
| Q37373088 | The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis |
| Q60609561 | Therapeutic developments in pancreatic cancer: current and future perspectives |
| Q37408595 | Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis |
| Q86643084 | Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients |
| Q90115527 | Treatment of hepatic pancreatic ductal adenocarcinoma metastases with high-dose-rate image-guided interstitial brachytherapy: a single center experience |
| Q47579248 | Treatment of pancreatic insufficiency using pancreatic extract in patients with advanced pancreatic cancer: a pilot study (PICNIC). |
| Q51772050 | Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. |
| Q56961445 | Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma |
| Q39030076 | Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer. |
| Q36095529 | Update on the Management of Pancreatic Cancer in Older Adults |
| Q28087060 | Update on the management of pancreatic cancer: surgery is not enough |
| Q64100420 | Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis |
| Q52654643 | Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. |
| Q42776799 | Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma |
| Q63865739 | Use of Machine-Learning Algorithms in Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse. |
| Q35803650 | Use of a novel herbal medicine in a 75-year-old woman with multi-metastatic pancreatic cancer: A case report and review of the literature |
| Q94503614 | Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy |
| Q55119439 | Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. |
| Q26774641 | Viro-immune therapy: A new strategy for treatment of pancreatic cancer |
| Q92267402 | Which is the optimal adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma?: A protocol for a network meta-analysis of randomized controlled trials |
| Q42830530 | Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer? |
| Q38821635 | Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma? |
| Q52839338 | [Choosing wisely recommendations in gastroenterology]. |
| Q57172464 | [Pancreatic ductal adenocarcinoma] |
| Q58561906 | [Personalized cancer medicine : Biomarkers for molecular therapy stratification in pancreatic carcinoma] |
| Q53194479 | [R1 resection for pancreatic carcinoma]. |
| Q47114745 | miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer. |
| Q34499655 | α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study |
| Q57784318 | β-Catenin expression is associated with cell invasiveness in pancreatic cancer |
Search more.